Allakos (NASDAQ:ALLK) Cut to Hold at Citizens Jmp

Citizens Jmp downgraded shares of Allakos (NASDAQ:ALLK) from a strong-buy rating to a hold rating in a research report report published on Monday,Zacks.com reports.

Allakos Price Performance

Shares of ALLK stock opened at $0.25 on Monday. The company has a fifty day moving average price of $1.02 and a two-hundred day moving average price of $0.90. Allakos has a one year low of $0.23 and a one year high of $1.69. The stock has a market cap of $22.69 million, a P/E ratio of -0.13 and a beta of 0.86.

Allakos (NASDAQ:ALLK) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. As a group, equities research analysts anticipate that Allakos will post -1.16 EPS for the current fiscal year.

Institutional Trading of Allakos

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 DIFC Ltd acquired a new stake in Allakos during the second quarter worth approximately $25,000. Cubist Systematic Strategies LLC bought a new stake in Allakos in the 2nd quarter valued at $55,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Allakos in the 2nd quarter valued at $112,000. RBF Capital LLC increased its position in Allakos by 45.9% during the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after buying an additional 160,529 shares during the period. Finally, GSA Capital Partners LLP lifted its holdings in shares of Allakos by 11.9% during the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock worth $519,000 after buying an additional 84,750 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.